Secondary hyperparathyroidism. Conservative management in patients with renal insufficiency.
In three patients with advanced renal disease (inulin clearance, 4.6 to 9.1 ml/min) and systemic manifestations of secondary hyperparathyroidism, concentrations of serum calcium and phosphorus were maintained within our normal limits (9 and 3.5 mg/100 ml, respectively) with phosphate-binding antacids and orally given calcium carbonate. The result was progressive disappearance of symptoms related to secondary hyperparathyroidism, healing of osteitis fibrosa, and normalization of serum concentrations of immunoreactive parathyroid hormone.
D000284:Administration, Oral; D000328:Adult; D000863:Antacids / Q000627:therapeutic use*; D002118:Calcium / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D002254:Carbonates / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000150:complications / Q000188:drug therapy*; D007444:Inulin; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010002:Osteitis Fibrosa Cystica / Q000188:drug therapy; D010281:Parathyroid Hormone / Q000097:blood / Q000276:immunology; D010710:Phosphates / Q000097:blood
D000863:Antacids; D002254:Carbonates; D010281:Parathyroid Hormone; D010710:Phosphates; D007444:Inulin; D002118:Calcium